Discontinued — last reported Q4 '22
Products & Services · Amortization
Lynparza — Amortization
This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalLower is better
VolatilityStable
First reportedQ1 2020
Last reportedQ4 2022
How to read this metric
An increase in amortization expense typically reflects the ongoing recognition of costs from recent acquisitions or intangible asset investments, while a decrease may indicate that assets are becoming fully amortized.
Detailed definition
This metric represents the systematic allocation of the cost of intangible assets associated with the Lynparza product l...
Peer comparison
Comparable to 'Amortization of Intangible Assets' found in the segment reporting or notes to financial statements of other pharmaceutical companies with acquired drug portfolios.
Metric ID:
mrk_segment_lynparza_amortizationHistorical Data
4 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | |
|---|---|---|---|---|
| Value | $250.00M | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | -100.0% | — | — |
Range$0.00 – $250.00M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s lynparza — amortization?
- Merck & Co. (MRK) reported lynparza — amortization of $0.00 in Q4 2022.
- What does lynparza — amortization mean?
- The periodic non-cash expense recognized to account for the gradual consumption of the value of intangible assets related to the Lynparza product.